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a b s t r a c t
Rhesus cytomegalovirus (RhCMV) 68-1 is the prototypic strain of RhCMV that has been used for
pathogenesis and vaccine development. We determined the complete sequence of the RhCMV 68-1 UL/b′
region directly from the original urine from which RhCMV 68-1 was isolated in 1968, and compared
it to other RhCMVs. The laboratory passaged RhCMV 68-1 has inversions, deletions, and stop codons in
UL/b′ that are absent in the original isolate and other low passage RhCMV isolates. Fourteen of the 17
open reading frames (ORFs) in 68-1 UL/b′ in the original isolate share 495% amino acid identity with
low passage RhCMV. The original isolate retains 6 ORFs that encode α-chemokine-like proteins, including
RhUL146 and RhUL146b that share only 92% and 81% amino acid identity, respectively, with a
contemporary low passage RhCMV isolate. Identiﬁcation of the original RhCMV 68-1 UL/b′ sequence is
important for using RhCMV 68-1 in pathogenesis and vaccine studies.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Human cytomegalovirus (HCMV) causes congenital disease in
infants and neonates, mononucleosis in adults, and severe disease
in transplant recipients and immunocompromised patients
(Mocarski et al., 2013). Currently, an effective vaccine for human
CMV (HCMV) has not been licensed, although it has been given a
priority 1 status by the Institute of Medicine (Stratton et al., 1999).
Rhesus cytomegalovirus (RhCMV) infection in rhesus macaques
mimics infection of HCMV in humans, making RhCMV the most
practical animal model that most closely resembles HCMV (Früh
et al., 2013; Powers and Fruh, 2008). Like HCMV, most infections
with RhCMV are asymptomatic, result from mucosal contact with
bodily ﬂuids containing the virus, and develop into a lifelong
latent infection. Experimental infection of macaques with RhCMV
can cause congenital disease in neonates and disseminated
disease in immunocompromised animals (Yue and Barry, 2008).
RhCMV, like HCMV, is accompanied by hematologic changes that
may include monocytosis, neutropenia, and lymphocytosis. Both
RhCMV and HCMV are common in their host populations (Andrade
et al., 2003; Bate et al., 2010; Kessler et al., 1989; Vogel et al., 1994).
About 80% of RhCMV open reading frames (ORFs) have orthologs
in HCMV and ≥ 90% have orthologs at the level of protein families,
strongly suggesting a common ancestor (Hansen et al., 2003;
Malouli et al., 2012; Oxford et al., 2008; Rivailler et al., 2006).
Comparison of the sequence of RhCMV ORFs with those from
other Old World monkey CMV isolates showed a high level of
conservation which was validated by identiﬁcation of virion
proteins using mass spectrometry (Davison et al., 2013; Malouli
et al., 2012). Both RhCMV and HCMV contain a highly labile region
labeled UL/b′ that encodes proteins important in cellular tropism
and immune evasion. The UL/b′ region of RhCMV and HCMV
frequently undergoes mutation during in vitro passage when virus
is propagated in ﬁbroblasts (Hansen et al., 2003; Oxford et al.,
2008; Revello and Gerna, 2010; Rivailler et al., 2006).
RhCMV was ﬁrst isolated from the urine of healthy rhesus
macaques (Macaca mulatta) in 1968, propagated in ﬁbroblasts, and
the resulting strain was termed 68-1 (Asher et al., 1969, 1974). The
cytopathic effects observed in vitro were similar to those seen
with HCMV and African green monkey CMV strains, with refractile
rounding and sloughing of infected human fetal lung ﬁbroblasts.
RhCMV 68-1, deposited in the American Type Culture Collection
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after subsequent passages in primary rhesus ﬁbroblasts, was comp-
letely sequenced in 2003 (Hansen et al., 2003). Interestingly, after
propagation in ﬁbroblasts, RhCMV 68-1 was reported to replicate
poorly in endothelial and epithelial cells, which mimicked the
in vitro effects of highly passaged HCMV laboratory strains like
AD169 (Lilja and Shenk, 2008). Subsequently, it was determined
that the UL/b′ region of laboratory passaged strains of HCMV and
RhCMV (namely 68-1 and 180.92) have large deletions compared
with low passage (or unpassaged) isolates (Cha et al., 1996; Dolan
et al., 2004; Hansen et al., 2003; Murphy et al., 2003; Rivailler et al.,
2006). The UL/b′ region of CMV contains UL128, UL130, and
UL131A, which are required for infection of endothelial cells and
epithelial cells (Hahn et al., 2004; Lilja and Shenk, 2008; Ryckman
et al., 2006; Wang and Shenk, 2005) as well as other viral proteins
which are likely important for virus structure (Spaderna et al.,
2005), signaling (Cheung et al., 2005), virus spread (Penfold et al.,
1999), immune evasion (Wills et al., 2005), and latency (Goodrum
et al., 2007). With the exception of replication of virus in endothelial
and epithelial cells, the other functions of the UL/b′ region have not
been formally shown to be conserved in RhCMV. Only RhCMV
laboratory strains that retain a fully intact UL/b′ set of genes are
shed at high levels and are easily transmitted from animal to animal
in primate colonies (Oxford et al., 2011).
RhCMV68-1 has been used to study RhCMV pathogenesis
(Lockridge et al., 1999), as a model for CMV vaccine development
(Yue et al., 2007), and most recently as a vector to induce long-term
(Hansen et al., 2011) and very broad CD8 T cell responses to SIV
(Hansen et al., 2013). To better understand the evolution of the
prototype strain of RhCMV68-1, we determined the sequence of the
UL/b′ region of the virus directly from the original urine obtained in
1968 by Asher et al. and compared it with the sequence of other
strains of RhCMV, other primate CMVs, and HCMV.We found that the
68-1 UL/b′ ORF organization and sequence closely aligns with
sequences from low passage contemporary RhCMV isolates, and that
the inversions and deletions in the laboratory strain of 68-1 are
notably absent. Analysis of the original sequence of the UL/b′ region
of 68-1 suggests that the regions important for cellular tropism and
immune evasion are highly sensitive to in vitro selection, and that the
greatest variance occurs amongst the CXC-chemokine-like genes
within the region.
Results and discussion
Sequence of the UL/b′ region from RhCMV 68-1-P0
Asher originally obtained urine from 9 juvenile rhesus
macaques in 1968 (Asher et al., 1969). Animals were hydrated
with intravenous ﬂuid and given mannitol to induce diuresis.
Penicillin and streptomycin were added to the urine and a portion
was frozen at 701 C. Urine that had not been frozen was serially
diluted, and 0.2 ml aliquots of undiluted or diluted urine were
used to inoculate stationary WI38 cell (fetal human lung diploid
ﬁbroblast) tube cultures. CPE was ﬁrst noted in cells inoculated
with diluted urine from a female macaque on day 17 and virus
from undiluted urine from the same animal was passaged in WI38
cell tube cultures and deposited in the ATCC as RhCMV 68-1
(Asher et al., 1974). Despite repeated attempts we were unable to
isolate infectious virus from the urine. However, sufﬁcient virus
DNA remained in the urine sample to amplify by PCR; the copy
number of RhCMV DNA in the urine was 18.3 copies of RhCMV
DNA/uL by real time-PCR. We isolated DNA from the urine and
obtained overlapping PCR products that corresponded to the UL/b′
region of RhCMV 68-1-P0 (passage 0). The complete region of
RhCMV 68-1-P0 UL/b′ (GenBank accession #KF011492) is 12.9
kilobase pairs with a GC content of 46% and encodes 17 ORFs in the
same orientation which are most conserved with low-passage
RhCMV isolates from naturally infected macaques (Malouli et al.,
2012; Oxford et al., 2008; Fig. 1, Table 1). While RhCMV 68-1-ATCC
is missing ORFs UL128, UL146a, UL146b, rh161.1 and a portion of
UL130, the RhCMV 68-1-P0 strain contains full-length sequences
for each of these ORFs. The 5′ end of RhCMV 68-1-P0 UL/b′ has a
22 nucleotide sequence repeated 19 times, 16 of which are direct
repeats. These sequences are conserved throughout various strains
of simian CMVs (Supplemental Table 1, nucleotide polymorphisms
underlined and bolded) and may encode regulatory miRNAs
(Hancock et al., 2012).
Comparison of RhCMV 68-1-P0 with other simian CMV UL/b′ ORFs
The 17 ORFs encoded in RhCMV 68-1-P0 UL/b′ were com-
pared with their orthologs in other simian CMVs based on the
Fig. 1. Genomic arrangement of UL/b′ open reading frames (ORFs) sequenced from the original source of RhCMV 68-1-P0 compared with passaged RhCMV 68-1 deposited in the
ATCC (68-1-ATCC). Nucleotide numbering of RhCMV 68-1-ATCC (based on Rivailler et al., 2006) is shown at the top for comparison. The genomic structures, consensus regions (A-D),
and predicted ORFs are depicted based on previously reported sequences of RhCMVs from low passage or unpassaged isolates (Rivailler et al., 2006; Oxford et al., 2008). RhCMV 68-
1-P0 ORFs are on the complementary strand. Gray shaded ORFs are present or have a highly homologous region in 68-1-ATCC, while black shaded ORFs are absent from 68-1-ATCC.
White regions joined by lines are proposed exons. The splice variant for UL130 is indicated as UL130/rh157.4. A putative microRNA region (22-mer repeated 19 times, dotted box) is
highlighted at the 5′ end of the contig and is also present in the 68-1-ATCC strain. The ﬁgure is based on that from Oxford et al. (2008).
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bit scores to establish if one ORF is more closely related to a
certain strain of CMV. Bit scores (calculated using NCBI BLASTp)
are normalized log-scale sequence alignment scores that com-
pare sequence alignments taking into account maximum
sequence identity (longest stretch of matching amino acids)
and total sequence identity (overall number of matching amino
acids); the higher the number, the less likely the alignment was
to have occurred by pure chance and the more likely the
sequences are to have originated from similar sources. The bit
scores for RhCMV 68-1-P0 UL/b′genes show that these ORFs are
most similar to those in RhCMV CNPRC (not passaged in vitro),
68-1-ATCC, and 22659 (a low passage isolate) (Supplemental
Fig. 1, data not shown). As reported previously, RhCMV shares
greatest homology outside of its species with cynomolgus
macaque cytomegalovirus (CynoCMV) and does not have as
high of a degree of homology with chimpanzee CMV, HCMV, or
African green monkey CMV (Table 1). RhCMV has even less
homology with squirrel monkey CMV and aotus monkey CMV.
Amino acid alignment of ORFs truncated or missing from 68-1-ATCC
UL/b′
Comparison of ORFs in UL/b′ between RhCMV 68-1-P0 and
68-1-ATCC indicates that ORFs UL128, UL146a, UL146b, and
rh161.1 are missing from 68-1-ATCC, while ORF UL130 (which
encodes a membrane glycoprotein) is truncated. RhCMV 68-1-P0
encodes UL146, UL146a, UL146b, UL147, rh161.1 and rh161.2,
which are putative CXC chemokines (Alcendor et al., 2009;
Oxford et al., 2008). These genes are thought to have arisen from
a single ancestral CXCL gene that gave rise to daughter genes and
subsequent gene duplications (Alcendor et al., 2009). RhCMV 68-
1-ATCC, encodes only UL146, UL147, and rh161.2 (which was
formerly termed rh161, Oxford et al., 2008, in 68-1-ATCC). HCMV
UL146 activates CXCR1 and CXCR2, probably to attract neutrophils
that carry virus to endothelial cells (Lüttichau, 2010), while UL147
is also important for neutrophil chemotaxis (Penfold et al., 1999).
UL146a is an ELR CXC chemokine, which suggests that the
Table 1
Amino acid percent maximum identity comparison of RhCMV 68-1-P0 UL/b′ open reading frames to other CMV isolates.
RhCMV
ORF
Protein class Proposed function % AA maximum identity of 68-1-P0 vs. other CMV isolates
RhCMV
68-1
(ATCC)
RhCMV
CNPRC
RhCMV
22659
RhCMV
180.92
Cyno
CMV
(Ottawa)
Chimp
CMV
HCMV
(Merlin)
CeHV-5
2715
SaHV-
3
SaSHV
AoHV-
1
S43E
UL128
Membrane
glycoprotein
Pentamer envelope complex
Essential for endo/epithelial cell
tropism
NHa 99 100 99 97 36 42b 11 4 6
UL130
Membrane
glycoprotein
Pentamer envelope complex
Essential for endo/epithelial cell
tropism
100c 98 99 99 87 80 80 40 20 18
UL131A
Membrane
glycoprotein
Pentamer envelope complex
Essential for endo/epithelial cell
tropism
100c 93 91 95 97 78 60 31 16 22
UL132
(rh160)
Membrane
glycoprotein
Essential for epithelial cell tropism 99 99 99 99 95 35 40 54 16 15
UL148
(rh159)
Potential CXC
(α) Chemokine
Potentially encoded as a large
transcript with UL146-UL132
100 99 99 100d 89 55 42 36 10 9
UL147
(rh158)
Potential CXC
Chemokine
Homology to HCMV vCXCL2α-
chemokine like protein
100 97 99 NH 98 44 41 42 NH NH
UL146
Potential CXC
Chemokine
Homology to HCMV vCXCL1
α-chemokine like protein
100 92 100 NH 79
UL146: 35
UL146A:
56
26 50 NH NH
UL146a
Potential CXC
Chemokine
α-chemokine like protein NH 98 99 NH 90 33
UL146:
57
NH NH NH
UL146b
Potential CXC
Chemokine
α-chemokine like protein NH 81 100 NH 80 NH NH 38 NH NH
rh161.1
Potential CXC
Chemokine
Possible duplication of rh161.2
α-chemokine like protein
34e 98 100 NH 93 NH NH 35 NH NH
rh161.2e
Potential CXC
Chemokine
α-chemokine like protein 100e 98 100 NH 97 NH NH
UL146G:
32
NH NH
UL145
(rh162)
Potential
kinase
Highly conserved with putative PKC
and CK II sites
100 100 99 NH 99 65 65 86 36 36
UL144
(rh163)
Membrane
Receptor
TNFR-like protein 100 97 99 NH 99 43 63 43 NH NH
UL141
(rh164)
Membrane
glycoprotein
Downregulate cell surface
expression of CD155 and CD112
100 99 99 NH 97 47 67 58 NH NH
rh165
Membrane
glycoprotein
Possible duplication of tandem
ORFs (rh165, 166, 167)
100 99 96 NH 95 NH NH NH NH NH
rh166
Membrane
glycoprotein
Possible duplication of tandem
ORFs (rh165, 166, 167)
100 99 98 NH 96 NH NH NH NH NH
rh167
Membrane
glycoprotein
Possible duplication of tandem
ORFs (rh165, 166, 167)
100 98 NH 97d 95 NH NH NH NH NH
GenBank numbers: Rhesus CMV (RhCMV) 68-1-P0 (KF011492); RhCMV 68-1-ATCC (AY186194.1); RhCMV CNPRC (EF990255.1); RhCMV 22659 (EU130540.1); RhCMV 180.92
(DQ120516.1); Cynomolgus macaque CMV (CynoCMV)-Ottawa (JN227533.1); Chimpanzee CMV (Chimp CMV) (AF480884.1); Human CMV (HCMV)-Merlin (AY446894.2);
African green monkey CMV (CeHV-5) 2715 (FJ483968); Squirrel monkey CMV (SaHV-3) SqSHV (FJ483967); Aotus monkey CMV (AoHV-1) S34E (FJ483970).
a NH¼No homolog found in comparison sequence.
b ADB84700.1 (low-passage clinical isolate used due to mutation in UL128 of Merlin).
c Comparison made using nucleotide alignment.
d ORF truncated in comparison sequence.
e Comparison made using rh161.2 (which was formerly termed rh161 in 68-1-ATCC, Oxford et al., 2008).
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protein is important for leukocyte migration (Ebert et al., 2005),
while UL146b is an ELRþ CXC chemokine, which implies that
it can interact with CXCR1 and CXCR2 and induce migration of
neutrophils (Kobayashi, 2008). rh161.1 and rh161.2 are thought to
be the result of a gene duplication event. While most other
proteins in UL/b′ share 495% amino acid identity between
RhCMV 68-1-P0 and other RhCMV isolates, genes encoding the
putative CXC chemokines are the least conserved between differ-
ent RhCMV isolates. UL146b and UL146 share only 81% and
92% amino acid identity, respectively, between RhCMV 68-1-P0
and RhCMV CNPRC (Table 1), and rh161.1 in RhCMV 68-1-P0
and rh161.2 from RhCMV 68-1-ATCC share only 34% amino acid
identity.
UL128 is a glycoprotein, derived from exon splicing that is one
of the components of the CMV pentameric complex (consisting of
UL128, UL130, UL131A, gH and gL) important for epithelial and
endothelial cell tropism (Lilja and Shenk, 2008; Ryckman et al.,
2006). Antibody to the pentameric complex is the predominant
component of CMV neutralizing antibody in human sera (Fouts
et al., 2012; Genini et al., 2011; Macagno et al., 2010), and
immunization of monkeys with the pentameric complex induces
broadly neutralizing antibody in the animals (Wussow et al.,
2013). The RhCMV 68-1-P0 UL/b′ region contains a full-length
copy of UL128, which includes all three exons, and its amino acid
sequence is highly conserved among other RhCMV and CynoCMV
isolates (Supplemental Fig. 2). While the initial description of the
CynoCMV Ottawa strain did not report having all three exons
(Marsh et al., 2011), analysis of the nucleotide sequence revealed
that CynoCMV does have a potential third exon in UL128 (Supple-
mental Fig. 2, gray highlight).
UL130 is also a glycoprotein produced from exon splicing that is
part of the pentameric complex. While the spliced version of
UL130 from RhCMV 68-1-P0 aligns well with other RhCMV and
CynoCMV sequences (Supplemental Fig. 3), RhCMV 68-1-P0 has a
deletion of 16 amino acids compared with other isolates, which
likely is a result of a duplication event. RhCMV 68-1-ATCC only has
the ﬁrst exon of UL130, and is missing the second exon which has
been termed rh157.4 (Oxford et al., 2008). Although not reported
in the initial publications (Marsh et al., 2011; Rivailler et al.,
2006), analysis of both RhCMV 180.92 and CynoCMV nucleotide
sequences reveals that each contains the second exon of UL130
(Supplemental Fig. 3, gray highlight).
UL131A is an another glycoprotein within the pentameric
complex. Of the three glycoproteins in this complex encoded
by the UL/b′ region, UL131A shares the least homology between
RhCMV 68-1-P0 and other RhCMV isolates ranging from 91% to
95% amino acid identity.
Conclusions
The organization and sequence of the UL/b′ region from the
original isolate of RhCMV 68-1 (RhCMV 68-1-P0) closely aligns
with contemporary wild-type isolates of RhCMV, and inversions
and deletions in the laboratory strain of 68-1-ATCC relative to
contemporary isolates are absent. The regions in the UL/b′ region
of RhCMV 68-1-P0 important for cellular tropism and immune
evasion are highly sensitive to in vitro selection and the greatest
divergence occurs in the CXC-chemokine-like genes.
Materials and methods
RhCMV viral DNA was isolated from urine using the QIAamps
Viral RNA Mini Kit (QIAGEN Inc., Valencia, CA) according to the
manufacturer's instructions. RhCMV genome copy number in the
urine was determined by real-time PCR using TaqMans FAM(6-
carboxyﬂuorescein)/TAMRA(tetramethylrhodamine) technology
(Applied Biosystems, Foster City, CA), using primers 5′-TGCGTAC-
TATGGAAGAGACAATGC (gB RT Forward) and 5′-ACATCTGGC
CGTTCAAAAAAAC (gB RT Reverse) and a FAM-tagged probe
5′-FAM/ CCAGAAGTTGCGCATCCGCTT to determine RhCMV gB
copy number.
The UL/b′ region of RhCMV 68-1 was ampliﬁed by PCR (primers
listed in Supplemental Table 2). Overlapping PCR products
obtained by using the HotStarTaqs DNA polymerase kit (QIAGEN
Inc.) were gel puriﬁed (GenEluteTM Agarose Spin Column, Sigma-
Aldrich, St. Louis, MO). Amplicons were cloned using the Promega
pGEMs-T Easy Vector System (Madison, WI) and sequenced using
either external T7 and SP6 or internal primers. At least two clones
for each amplicon were sequenced. If clones from amplicons were
not obtained, the isolated fragments were sequenced directly.
Sequencing reactions were assembled using Lasergene SeqMan
Pro (DNASTAR, Inc., Madison, WI). The UL/b′ sequence from
RhCMV 68-1-P0 has been deposited in Genbank (accession num-
ber KF011492).
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